Australia-based startup 4DMedical has announced that its latest imaging technology, CT:VQ™ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets.
In a separate but concurrent announcement, 4DMedical has secured firm commitments from select institutional investors for an AU$83 million single-tranche private placement. This additional capital will support the company's growth strategy, particularly the expansion of CT:VQ™ in Europe.
CT:VQ™ is the world's first and only non-contrast, ventilation-perfusion imaging technology, providing quantitative functional lung insights from routine non-contrast CT scans without the need for radiotracers or specialised nuclear medicine infrastructure.
Pulmonary disease is fundamentally functional, defined by abnormalities in ventilation and perfusion, yet most routine imaging available to radiologists and pulmonologists remains purely structural. CT:VQ™ bridges that gap by generating ventilation and perfusion maps allowing clinicians to visualise regional lung function with the anatomical clarity of CT.
4DMedical estimates that approximately 400,000 nuclear VQ scans are performed annually across the EU, underscoring the scale of clinical need.
